The Medical Scientist Training Program (MSTP) at the Albert Einstein College of Medicine (Einstein) is one of the nation's oldest. From the start, our goal has been to train a diverse group of outstanding students to become future leaders of academic medicine and medical research. Continuously funded by the National Institutes of Health since 1964, the Einstein MSTP has 516 illustrious Alumni with careers spanning the spectrum from basic science research to clinical medicine and many variations in between.

Today, the Einstein MSTP is still unique. Larger than most other MSTPs, it fosters a strong academic and social community within the college. While large enough to be an independent academic unit, the program is still small enough to provide students with the individual attention their unique careers require.

The MSTP recognizes that the successful physician-scientist training is not simply medical school plus graduate training. The program integrates MSTP-specific courses with medical and graduate courses, during the first 18 months of preclinical course work. Integration continues in the PhD thesis years through weekly involvement in the MSTP Continuity Clinic. Students have outstanding publications and residency placements.

The Einstein MSTP encourages applications from all individuals. The College's Diversity and Inclusion Strategic Plan for Excellence states, "At Einstein, we value all people and perspectives that make us unique and increase our diversity at large. Consistent with its focus on social justice, Albert Einstein College of Medicine reaffirms its commitment to recruiting, retaining, and advancing individuals from historically underrepresented and marginalized minority groups in the scientific and medical professions. At the College of Medicine, this includes, (in no particular order, and is not limited to) women, individuals who are Black, Latino/Latina; Pacific Islander or indigenous Americans; individuals from new immigrant populations; individuals with both apparent and nonapparent disabilities; all sexual and gender minorities, including lesbian, gay, bisexual, asexual and queer people as well as transgender, gender-nonconforming and intersex individuals; religious minorities; and individuals from economically disadvantaged backgrounds."

Predoctoral Fellowships

  • Daniella Miller NIH NRSA F30 Fellowship, “Investigation of Chromatin Modifiers to Elucidate the Phenotypic Variability of Congenital Heart Disease in Patients with 22q11.2 Deletion Syndrome” (Sponsor, Bernice Morrow, Genetics)
  • Elliot Kim F30 NRSA Fellowship, “Effects of locomotion on visual inter-areal processing” (Sponsor, Adam Kohn, Neuroscience)
  • Blake Ebert NIH NRSA F30 Fellowship, “Tet-mediated DNA hydroxylation vs formylation and carboxylation in NSC biology” (Sponsor, Meelad Dwalaty, Genetics)
  • Brett Bell NIH NRSA F30 Fellowship, "Anti-Complement Immunotherapy for Pancreatic Cancer" (Sponsor, Chandan Guha, Pathology)
  • Erik Guillen NIH NRSA F31 Fellowship, "Impact of T cell receptor signaling on memory CD8+ T cell stemness" (Sponsor, Gregoire Lauvau, Microbiology & Immunology)
  • Helen Jung NIH NRSA F30 Fellowship, "Strategies for next-generation flavivirus vaccine development" (Sponsor, Jon Lai, Biochemistry)
  • Riana Lo Bu NIH NRSA F31 Fellowship, "Dissecting GWAS Identified Risk Variants in Parkinson's Disease – Functional Role of GPNMB in the Pathogenesis of PD" (Sponsor, Frank Soldner, Neuroscience)


  • publications Mulholland CV, Wiggins TJ, Cui J, Vilchèze C, Rajagopalan S, Shultis MW, Reyes-Fernández EZ, Jacobs WR Jr, Berney M. Propionate prevents loss of the PDIM virulence lipid in Mycobacterium tuberculosis. Nat Microbiol. 2024 Jun; 9(6):1607-1618.
  • publications Nishimura CD, Corrigan D, Zheng XY, Galbo PM Jr, Wang S, Liu Y, Wei Y, Suo L, Cui W, Mercado N, Zheng D, Zhang CC, Zang X. TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors. Sci Adv. 2024 May 10; 10(19):eadk1857.
  • publications Rosean S*, Sosa EA*, O'Shea D, Raj SM, Seoighe C, Greally JM. Regulatory landscape enrichment analysis (RLEA): a computational toolkit for non-coding variant enrichment and cell type prioritization. BMC Bioinformatics. 2024 May 7; 25(1):179. (*contributed equally)
  • publications O'Leary K, Zheng D. Metacell-based differential expression analysis identifies cell type specific temporal gene response programs in COVID-19 patient PBMCs. NPJ Syst Biol Appl. 2024 Apr 5; 10(1):36.
  • publications Yu X, Benitez G, Wei PT, Krylova SV, Song Z, Liu L, Zhang M, Xiaoli AM, Wei H, Chen F, Sidoli S, Yang F, Shinoda K, Pessin JE, Feng D. Involution of brown adipose tissue through a Syntaxin 4 dependent pyroptosis pathway. Nat Commun. 2024 Apr 2; 15(1):2856.
  • publications Williams DKA, Christophers B, Keyes T, Kumar R, Granovetter MC, Adigun A, Olivera J, Pura-Bryant J, Smith C, Okafor C, Shibre M, Daye D, Akabas MH. Sociodemographic factors and research experience impact MD-PhD program acceptance. JCI Insight. 2024 Feb 8; 9(3):e176146.
  • publications Eligulashvili A, Darrell M, Gordon M, Jerome W, Fiori KP, Congdon S, Duong TQ. Patients with unmet social needs are at higher risks of developing severe long COVID-19 symptoms and neuropsychiatric sequela. Sci Rep. 2024 Apr 2; 14(1):7743.
  • publications Moore E, Bharrhan S, Rao DA, Macian F, Putterman C. Characterisation of choroid plexus-infiltrating T cells reveals novel therapeutic targets in murine neuropsychiatric lupus. Ann Rheum Dis. 2024 Mar 26:ard-2023-224689.